Free Trial

Regulus Therapeutics Q1 2023 Earnings Report

Regulus Therapeutics logo
$1.53 -0.06 (-3.77%)
(As of 05:45 PM ET)

Regulus Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Regulus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Regulus Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A
Your chance to get on the next “60-Second Trade” (Ad)

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Just head over here!

Regulus Therapeutics Earnings Headlines

No one’s talking about these Trump trades
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Regulus Therapeutics Reports Q3 2024 Financial Results
See More Regulus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Regulus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regulus Therapeutics and other key companies, straight to your email.

About Regulus Therapeutics

Regulus Therapeutics (NASDAQ:RGLS), a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

View Regulus Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings